CUSIP: 14875P107
Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
7,456,186
-
Share change
-
+252,543
-
Total reported value
-
$15,807,000
-
Price per share
-
$2.12
-
Number of holders
-
24
-
Value change
-
+$774,935
-
Number of buys
-
14
-
Number of sells
-
9
Quarterly Holders Quick Answers
What is CUSIP 14875P107?
CUSIP 14875P107 identifies CATB - CATABASIS PHARMACEUTICALS IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2017
-
Previous quarter:
Q2 2017
Recent filing periods for CUSIP 14875P107:
Institutional Holders of CATABASIS PHARMACEUTICALS IN - COM (CATB) as of Q3 2017
As of 30 Sep 2017,
CATABASIS PHARMACEUTICALS IN - COM (CATB) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,456,186 shares.
The largest 10 holders included
SV Health Investors, LLC, Clarus Ventures, LLC, VANGUARD GROUP INC, SPHERA FUNDS MANAGEMENT LTD., WEDBUSH SECURITIES INC, Alyeska Investment Group, L.P., RENAISSANCE TECHNOLOGIES LLC, OPPENHEIMER & CO INC, Virtu Financial LLC, and A.R.T. Advisors, LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.